View
1.830
Download
3
Category
Tags:
Preview:
DESCRIPTION
For an Executive Summary of this report please contact ediz.ibrahim@visiongain.com (+44 (0)20 7549 9976) or refer to our website: https://www.visiongain.com/Report/1338/Asthma-and-COPD-Therapies-Market-Forecast-2014-2024
Citation preview
www.visiongain.com
Contents
1. Report Overview
1.1 Global Asthma and COPD Therapies Market Overview
1.2 Global Asthma and COPD Therapies Market Segmentation
1.3 Why You Should Read This Report
1.4 How This Report Delivers
1.5 Key Questions Answered by This Analytical Report
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Visiongain Reports
1.10 About Visiongain
2. Introduction to Asthma and COPD Therapies
2.1 The Pharmaceutical Industry: a Very Brief Overview
2.2 Overview of Respiratory Diseases
2.2.1 Classifying Respiratory Diseases: Obstructive and Restrictive
2.3 What is Asthma?
2.3.1 Trends in Asthma Prevalence
2.3.2 Pathophysiology of Asthma
2.3.3 Symptoms of Asthma
2.3.4 Causes and Triggers for Asthma
2.3.5 Treatment of Asthma
2.3.6 Guidelines for Asthma Treatment
1. Report Overview
2. Introduction to Asthma and COPD Therapies
www.visiongain.com
Contents
2.3.7 Drug Treatments for Asthma
2.3.8 Drug Delivery Methods in Asthma
2.4 What is Chronic Obstructive Pulmonary Disease (COPD)?
2.4.1 Trends in COPD Prevalence
2.4.2 Pathophysiology of COPD
2.4.3 Signs and Symptoms of COPD
2.4.4 Treatment of COPD
2.4.5 Drug Treatments for COPD
2.4.6 Guidelines for COPD Treatment
2.5 Major Drug Classes in the Treatment of Asthma and COPD
2.5.1 Bronchodilators
2.5.1.1 Beta2-Agonists
2.5.1.2 Anticholinergics
2.5.2 Anti-Inflammatory Drugs
2.5.2.1 Corticosteroids
2.5.2.2 Leukotriene Receptor Antagonists
2.5.2.3 Monoclonal Antibodies in the Treatment of Respiratory Disease
2.5.3 Combination Drugs
2.5.4 Drugs for Allergic Rhinitis
2.6 Phases of Clinical Trials
2.7 Scope of this Report
2.8 Currency Exchange Rates in This Report
www.visiongain.com
Contents
3. Asthma and COPD Therapies: World Market 2014-2024
3.1 The World Respiratory Drugs Market by Therapeutic Area
3.2 The World Asthma and COPD Therapies Market in 2013
3.2.1 Leading Asthma and COPD Therapies
3.2.2 Leading Companies in the Asthma and COPD Therapies Market
3.3 World Asthma and COPD Therapies Market: Sales Forecast by Therapeutic Area, 2014-2024
3.3.1 World Asthma Therapies Market: Sales Forecast 2014-2024
3.3.2 World COPD Therapies Market: Sales Forecast 2014-2024
3.4 World Asthma and COPD Therapies Market: Sales Forecast by Drug Class 2014-2024
3.5 Combination Drugs Lead the Asthma and COPD Therapies Market
3.6 How Will Segmental Market Shares Change to 2024?
3.6.1 World Asthma and COPD Therapies Market: Drivers and Restraints 2014-2024
3.7 Asthma and COPD Therapies: Trends and Developments
3.7.1 FDA Requires Replacement of CFC Inhalers with HFA Inhalers
3.7.2 The WISDOM Trial: Will Steroids Lose Their Role in COPD?
4. Leading National Markets 2014-2024
4.1 Regional Breakdown of the World Asthma and COPD Therapies Market
4.2 World Asthma and COPD Therapies Market: Regional Forecast 2014-2024
4.2.1 How Will Regional Market Shares Change to 2024?
4.3 National Breakdown of the World Asthma and COPD Therapies Market
4.4 World Asthma and COPD Therapies Market: National Markets Forecast 2014-2024
4.4.1 How Will National Market Shares Change to 2024?
3. Asthma and COPD Therapies: World Market 2014-2024
4. Leading National Markets 2014-2024
www.visiongain.com
Contents
4.5 The US Asthma and COPD Therapies Market 2014-2024
4.5.1 US Asthma and COPD Therapies Market Forecast 2014-2024
4.5.2 US Asthma and COPD Therapies Market: Trends and Developments
4.5.2.1 Increasing COPD Prevalence in the US
4.5.2.2 FDA Issues Draft Guidance on Generic Inhaler Bioequivalence
4.5.2.3 Pharmacy Benefit Managers Alter Formulary Status of Advair
4.6 Japanese Asthma and COPD Therapies Market 2014-2024
4.6.1 Japanese Asthma and COPD Therapies Market Forecast 2014-2024
4.6.2 Japanese Asthma and COPD Therapies Market: Trends and Developments
4.6.2.1 Generic Penetration to Reach 60% by 2018?
4.6.2.2 Japanese Pharmaceutical Industry Regulatory Reform
4.7 EU5 Asthma and COPD Therapies Market 2014-2024
4.7.1 German Asthma and COPD Therapies Market Forecast 2014-2024
4.7.2 French Asthma and COPD Therapies Market Forecast 2014-2024
4.7.3 UK Asthma and COPD Therapies Market Forecast 2014-2024
4.7.4 Italian Asthma and COPD Therapies Market Forecast 2014-2024
4.7.5 Spanish Asthma and COPD Therapies Market Forecast 2014-2024
4.7.6 EU5 Asthma and COPD Therapies Market: Trends and Developments
4.7.6.1 Germany: Reform of AMNOG Pharmaceutical Rebate Law
4.7.6.2 France: Social Security Finance Bill 2014
4.7.6.3 UK: Improving Asthma and COPD Patient Outcomes
4.7.6.4 Italy: Austerity Measures Limiting Growth
4.7.6.5 Spain: The Start of Recovery in the Spanish Economy
4.8 BRIC Asthma and COPD Therapies Market 2014-2024
www.visiongain.com
Contents
4.8.1 Chinese Asthma and COPD Therapies Market Forecast 2014-2024
4.8.2 Chinese Asthma and COPD Therapies Market: Trends and Developments
4.8.2.1 China’s Industrial Future and Asthma/COPD
4.8.2.2 Expansion of Healthcare Coverage and Reimbursement
4.8.2.3 Price Controls and the Anhui Model
4.8.3 Brazilian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.4 Brazilian Asthma and COPD Therapies Market: Trends and Developments
4.8.4.1 Increasing Access to Medicines
4.8.5 Indian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.6 Indian Asthma and COPD Therapies Market: Trends and Developments
4.8.6.1 Drug Prices Control Order 2013
4.8.6.2 Expansion of Healthcare Provision
4.8.7 Russian Asthma and COPD Therapies Market Forecast 2014-2024
4.8.8 Russian Asthma and COPD Therapies Market: Trends and Developments
4.8.8.1 No Embargo on Foreign Drug Imports
4.8.8.2 Pharma2020 and the Russian Pharmaceutical Industry
4.9 Mexican Asthma and COPD Therapies Market 2014-2024
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2014-2024
4.9.2 Mexican Asthma and COPD Therapies Market: Trends and Developments
4.9.2.1 Seguro Popular: Mexican Healthcare Reform
4.9.2.2 COFEPRIS: Regulatory Changes and Improvements
4.9.2.3 Mexico’s Agreement for Innovation
www.visiongain.com
Contents
5. Bronchodilator Monotherapy Market 2014-2024
5.1 Introduction to Bronchodilator Monotherapy
5.2 The Bronchodilator Monotherapy Market in 2013
5.2.1 Leading Bronchodilators in 2013
5.3 Bronchodilator Monotherapy: Market Forecast 2014-2024
5.4 How Will Market Shares by Drug Class Change to 2024?
5.5 The Short-Acting Beta2-Agonist (SABA) Market 2014-2024
5.5.1 Leading SABAs in 2013
5.5.2 SABAs: Market Forecast 2014-2024
5.5.3 Market Share of Leading SABAs to 2024
5.5.4 Ventolin (salbutamol, GSK)
5.5.4.1 Ventolin: Sales Forecast 2014-2024
5.5.5 ProAir (salbutamol, Teva)
5.5.5.1 ProAir: Sales Forecast 2014-2024
5.5.6 Proventil (salbutamol, Merck)
5.5.6.1 Proventil: Sales Forecast 2014-2024
5.5.7 Xopenex (levosalbutamol, Dainippon Sumitomo)
5.5.7.1 Xopenex: Sales Forecast 2014-2024
5.6 The Long-Acting Beta2-Agonist (LABA) Market 2014-2024
5.6.1 Leading LABAs in 2013
5.6.2 LABAs: Market Forecast 2014-2024
5.6.3 Market Share of Leading LABAs to 2024
5.6.4 Foradil (formoterol, Merck/Novartis)
5.6.4.1 Foradil: Sales Forecast 2014-2024
5. Bronchodilator Monotherapy Market 2014-2024
www.visiongain.com
Contents
5.6.5 Serevent (salmeterol, GSK)
5.6.5.1 Serevent: Sales Forecast 2014-2024
5.6.6 Arcapta/Onbrez (indacaterol, Novartis)
5.6.6.1 Arcapta/Onbrez: Sales Forecast 2014-2024
5.6.7 Brovana (arfomoterol, Dainippon Sumitomo)
5.6.7.1 Brovana: Sales Forecast 2014-2024
5.6.8 Striverdi (olodaterol, Boehringer Ingelheim)
5.6.8.1 Striverdi: Sales Forecast 2014-2024
5.7 The Anticholinergics Market 2014-2024
5.7.1 Leading Anticholinergics in 2013
5.7.2 Anticholinergics: Market Forecast 2014-2024
5.7.3 Market Share of Leading Anticholinergics to 2024
5.7.4 Spiriva (tiotropium, Boehringer Ingelheim)
5.7.4.1 Spiriva: Sales Forecast 2014-2024
5.7.5 Spiriva: Recent Developments
5.7.5.1 Safety Concerns and the UPLIFT Trial
5.7.5.2 Results of the POET Study
5.7.5.3 Competition from Combination Products
5.7.6 Atrovent (ipratropium, Boehringer Ingelheim)
5.7.6.1 Atrovent: Sales Forecast 2014-2024
5.7.7 Eklira/Tudorza/Bretaris (aclidinium, AstraZeneca/Forest/Menarini)
5.7.7.1 Eklira/Tudorza/Bretaris: Sales Forecast 2014-2024
www.visiongain.com
Contents
6. Anti-Inflammatory Drugs Market 2014-2024
6.1 Introduction to Anti-Inflammatory Drugs
6.2 The Anti-Inflammatory Drugs Market in 2013
6.2.1 Leading Anti-Inflammatory Drugs in 2013
6.3 Anti-Inflammatory Drugs: Market Forecast 2014-2024
6.4 How Will Market Shares by Drug Class Change to 2024?
6.5 The Corticosteroids Market 2014-2024
6.5.1 Leading Corticosteroids in 2013
6.5.2 Corticosteroids: Market Forecast 2014-2024
6.5.3 Market Share of Leading Corticosteroids to 2024
6.5.4 Flixotide/Flovent (fluticasone propionate, GSK)
6.5.4.1 Flixotide/Flovent: Sales Forecast 2014-2024
6.5.5 Pulmicort (budesonide, AstraZeneca)
6.5.5.1 Pulmicort: Sales Forecast 2014-2024
6.5.6 QVAR (beclometasone, Teva)
6.5.6.1 QVAR: Sales Forecast 2014-2024
6.5.7 Asmanex (mometasone, Merck)
6.5.7.1 Asmanex: Sales Forecast 2014-2024
6.6 The Anti-Leukotrienes Market 2014-2024
6.6.1 Leading Anti-Leukotrienes in 2013
6.6.2 Anti-Leukotrienes: Market Forecast 2014-2024
6.6.2.1 Market Share of Leading Anti-Leukotrienes to 2024
6.6.3 Singulair (montelukast, Merck)
6.6.3.1 Singulair: Sales Forecast 2014-2024
6. Anti-Inflammatory Drugs Market 2014-2024
www.visiongain.com
Contents
6.7 The Monoclonal Antibodies Market 2014-2024
6.7.1 Monoclonal Antibodies: Market Forecast 2014-2024
6.7.1.1 Market Share of Leading Monoclonal Antibodies to 2024
6.7.2 Xolair (omalizumab, Novartis/Roche)
6.7.2.1 Xolair: Sales Forecast 2014-2024
6.7.3 Cinquil (reslizumab, Teva)
6.7.3.1 Cinquil: Sales Forecast 2014-2024
6.7.4 Mepolizumab (Bosatria, GSK)
6.7.4.1 Mepolizumab: Sales Forecast 2014-2024
6.7.5 Benralizumab (MEDI-563, AstraZeneca/Kyowa Hakko Kirin)
6.7.5.1 Benralizumab: Sales Forecast 2014-2024
6.7.6 Lebrikizumab (RG3637, Roche)
6.7.6.1 Lebrikizumab: Sales Forecast 2014-2024
6.7.7 Dupilumab (REGN668, Regeneron/Sanofi)
6.7.7.1 Dupilumab: Sales Forecast 2014-2024
7. Combination Drugs Market 2014-2024
7.1 Introduction to Combination Drugs
7.1.1 Leading Combination Drugs in 2013
7.2 Combination Drugs: Market Forecast 2014-2024
7.3 How Will Market Shares by Drug Change to 2024?
7.3.1 Advair/Seretide (fluticasone/salmeterol, GSK)
7.3.1.1 Advair/Seretide: Sales Forecast 2014-2024
7.3.2 Symbicort (budesonide/formoterol, AstraZeneca)
7. Combination Drugs Market 2014-2024
www.visiongain.com
Contents
7.3.2.1 Symbicort: Sales Forecast 2014-2024
7.3.2.2 Symbicort: The SMART Concept
7.3.3 Combivent (ipratropium/salbutamol, Boehringer Ingelheim)
7.3.3.1 Combivent: Sales Forecast 2014-2024
7.3.4 Dulera (formoterol/mometasone, Merck)
7.3.4.1 Dulera: Sales Forecast 2014-2024
7.4 Recently Launched Combination Drugs
8. Leading Companies in the Asthma and COPD Therapies Market
8.1 Asthma and COPD Therapies: Increasing Competition
8.1.1 Leading Companies in Asthma and COPD in 2013
8.1.2 Leading Companies: Market Forecast 2014-2024
8.1.3 How Will Leading Companies’ Market Shares Change to 2024?
8.2 AstraZeneca
8.2.1 AstraZeneca: Asthma and COPD Therapies
8.2.2 AstraZeneca: Sales Forecast 2014-2024
8.2.3 AstraZeneca: Products in Development
8.2.4 AstraZeneca: Recent Developments
8.2.4.1 AstraZeneca Acquires Almirall’s Respiratory Portfolio
8.2.4.2 Acquisition of Pearl Therapeutics Expanded AstraZeneca’s Combination Drug
Pipeline
8.2.4.3 AstraZeneca Rejects Pfizer Takeover Bid
8.3 Boehringer Ingelheim
8.3.1 Boehringer Ingelheim: Asthma and COPD Therapies
8. Leading Companies in the Asthma and COPD Therapies Market
www.visiongain.com
Contents
8.3.2 Boehringer Ingelheim: Sales Forecast 2014-2024
8.3.3 Boehringer Ingelheim: Products in Development
8.3.4 Boehringer Ingelheim: Recent Developments
8.3.4.1 Expansion of Respimat Manufacturing Capacity
8.3.4.2 Respimat Safety Concerns and the TIOSPIR Study
8.3.4.3 Ben Venue Laboratories Shut Down
8.4 GSK
8.4.1 GSK: Asthma and COPD Therapies
8.4.2 GSK: Sales Forecast 2014-2024
8.4.3 GSK: Products in Development
8.4.4 GSK: Recent Developments
8.4.4.1 Breo/Relvar and Anoro: Recently Launched Combination Drugs
8.4.4.2 Arnuity Ellipta Approved in the US
8.4.4.3 GSK Divests OTC Products
8.4.4.4 GSK Asset Swap with Novartis to Restructure Consumer Health
8.4.4.5 GSK Presents Data on Eosinophil Levels and COPD
8.5 Merck & Co. (Merck)
8.5.1 Merck: Asthma and COPD Therapies
8.5.2 Merck: Sales Forecast 2014-2024
8.5.3 Merck: Products in Development
8.5.4 Merck: Recent Developments
8.5.4.1 Bayer Acquires Merck’s Consumer Health Business
8.5.4.2 FDA Rejects Singulair OTC Switch
8.5.4.3 Takeda Ended Co-Promotion of Daxas with Merck
www.visiongain.com
Contents
8.6 Novartis
8.6.1 Novartis: Asthma and COPD Therapies
8.6.2 Novartis: Sales Forecast 2014-2024
8.6.3 Novartis: Products in Development
8.6.4 Novartis: Recent Developments
8.6.4.1 Novartis Restructures Following Strategic Review
8.6.4.2 Novartis Presents Data on Ultibro and Seebri
8.6.4.3 Pfizer Promotes Two Novartis COPD drugs in the UK
8.7 Roche
8.7.1 Roche: Asthma and COPD Therapies
8.7.2 Roche: Sales Forecast 2014-2024
8.7.3 Roche: Products in Development
8.8 Teva
8.8.1 Teva: Asthma and COPD Therapies
8.8.2 Teva: Sales Forecast 2014-2024
8.8.3 Teva: Products in Development
8.8.4 Teva: Recent Developments
8.8.4.1 Launch of DuoResp Spiromax
9. Asthma and COPD Therapies Pipeline Analysis 2014-2024
9.1 A Strong Asthma and COPD Pipeline
9.2 The Bronchodilators Pipeline
9.2.1 Bronchodilators: Phase 3 Pipeline
9.2.1.1 PX1439 and PX1442 (Prosonix)
9. Asthma and COPD Therapies Pipeline Analysis 2014-2024
www.visiongain.com
Contents
9.2.1.2 PT001 (glycopyrronium, AstraZeneca)
9.2.1.3 Spiriva Respimat (tiotropium, Boehringer Ingelheim)
9.2.1.4 GW642444 (vilanterol, GSK)
9.2.1.5 KRP-AB1102 (aclidinium, Kyorin Pharmaceutical)
9.2.1.6 Seebri Breezhaler (glycopyrronium, Novartis/Vectura)
9.2.1.7 QVAR BAI (beclometasone, Teva)
9.2.1.8 Albuterol MDPI/Albuterol Spiromax (salbutamol, Teva)
9.2.2 Bronchodilators: Phase 2 Pipeline
9.2.3 Bronchodilators: Phase 1 and Preclinical Pipeline
9.3 The Anti-Inflammatory Drugs Pipeline
9.3.1 Anti-Inflammatory Drugs: Phase 3 Pipeline
9.3.1.1 PSX1001 and PSX1050 (fluticasone propionate pMDI, Prosonix)
9.3.1.2 Masitinib (tyrosine kinase inhibitor, AB Science)
9.3.1.3 Inhaled Alpha-1 Antitrypsin (Kamada/Chiesi Farmaceutici)
9.3.1.4 VR506 (fluticasone propionate DPI, Vectura)
9.3.1.5 Favolir (budesonide, Vectura)
9.3.2 Anti-Inflammatory Drugs: Phase 2 Pipeline
9.3.3 Anti-Inflammatory Drugs: Phase 1 Pipeline
9.3.4 Anti-Inflammatory Drugs: Preclinical Pipeline
9.4 The Combination Drugs Pipeline
9.4.1 Combination Drugs: Phase 3 Pipeline
9.4.1.1 PSX2005 (fluticasone/salmeterol, Prosonix)
9.4.1.2 LAS40464 (aclidinium/formoterol, AstraZeneca)
9.4.1.3 PT003 (glycopyrronium/formoterol, AstraZeneca)
www.visiongain.com
Contents
9.4.1.4 Tiotropium/Olodaterol Fixed-Dose Combination (LAMA/LABA, Boehringer
Ingelheim)
9.4.1.5 Easyhaler Combination Drugs (Orion)
9.4.1.6 VR632 (ICS/LABA, Vectura/Sandoz)
9.4.2 Combination Drugs: Phase 2 Pipeline
9.4.3 Combination Drugs: Phase 1 and Preclinical Pipeline
9.5 Other Asthma and COPD Drugs Pipeline
10. Qualitative Analysis of the Asthma and COPD Therapies Market
2014-2024
10.1 SWOT Analysis of the Asthma and COPD Therapies Market
10.2 Strengths
10.2.1 Increasing Prevalence and Disease Burden
10.2.2 High Costs of Treatment
10.2.3 The Changing Perception of COPD
10.2.4 Patient Education: Understanding the Severity of Respiratory Disease
10.2.5 Lifecycle Management Strategies to Counter Patent Expiry
10.2.6 Advanced Inhaler Technologies to Counter Generic Erosion
10.2.7 Developments in Diagnostics
10.2.7.1 Diagnostic Imaging: Parametric Response Mapping for COPD
10.2.7.2 Biological Markers in COPD
10.3 Weaknesses
10.3.1 Under-Diagnosis: the ‘Ghost Population’
10.3.2 Side-Effects of Drug Classes
10. Qualitative Analysis of the Asthma and COPD Therapies Market
2014-2024
www.visiongain.com
Contents
10.3.3 Patent Cliff for Devices
10.3.4 Low Patient Adherence
10.4 Opportunities
10.4.1 Patient Phenotyping and Personalised Medicine
10.4.2 A Strong R&D Pipeline
10.4.2.1 Ultra-Long-Acting Beta2-Agonists
10.4.2.2 Muscarinic Antagonists and Beta2-Agonists (MABAs)
10.4.2.3 Monoclonal Antibodies
10.4.2.4 LAMA/LABA Combinations
10.4.3 Growth in Emerging Markets
10.4.4 Opportunities in Telehealth
10.5 Threats
10.5.1 Patent Expiry and Generic Competition
10.5.2 Pharmacy Benefit Managers and Cost Control
10.5.3 The WISDOM Trial Could Reduce Steroid Use in COPD
10.6 Porter’s Five Forces Analysis of the Asthma and COPD Therapies Market
10.6.1 Rivalry Among Competitors [Medium]
10.6.2 Threat of New Entrants [Medium]
10.6.3 Power of Suppliers [Medium]
10.6.4 Power of Buyers [High]
10.6.5 Threat of Substitutes [Low]
www.visiongain.com
Contents
11. Research Interviews
11.1 Interview with Professor Clive Page, Professor of Pharmacology and Director of the Sackler
Institute of Pulmonary Pharmacology, King’s College London
11.1.1 Treating Different Phenotypes of Asthma and COPD
11.1.2 Personalised Medicine and Improved Existing Drug Classes
11.1.3 Phenotyping of Asthma/COPD, Diagnosis and Treatment
11.1.4 WISDOM Trial: Questioning the Role of Steroids in COPD
11.1.5 Monoclonal Antibodies in Severe Asthma
11.1.6 Healthcare Costs and the Importance of Prevention
11.1.7 Areas to Improve Diagnosis and Treatment of Asthma
11.1.8 The Importance of Adherence and Early Diagnosis
11.1.9 Developments in Alpha-1 Antitrypsin Deficiency
11.1.10 Other Trends and Developments in Asthma and COPD
11.2 Interview with a Company Developing Pipeline Drugs for Asthma and COPD
11.2.1 Asthma and COPD Treatments in 2014-2024
11.2.2 Personalised Therapies for Asthma and COPD?
11.2.3 Drivers and Restraints in the Market
11.2.4 The Outlook for the Asthma and COPD Market
11.3 Interview with Monica Fletcher, Chief Executive of Education for Health and Chair of the
European Lung Foundation (ELF), Sheffield, UK
11.3.1 The Importance of Education
11.3.2 Educating Healthcare Professionals and Patients
11.3.3 Missing the Diagnosis of COPD in Some Patient Populations
11.3.4 Global and Gender Issues in COPD
11. Research Interviews
www.visiongain.com
Contents
11.3.5 Improving Shared Understanding and Correct Inhaler Technique
11.3.6 The Growing Importance of Online Education
11.3.7 Engaging Patients Using Telehealth?
11.3.8 The Changing Impact of Education on Asthma and COPD
11.4 Interview with Daphne Tsitoura, Senior Medical Director, Clinical Drug
Development/Discovery Medicine, GlaxoSmithKline, UK
11.4.1 Unmet Needs in Asthma
11.4.2 The Asthma Market: Reaching Saturation?
11.4.3 Phenotypically-Tailored Therapies?
11.4.4 Difficulties with COPD Diagnosis
11.4.5 Importance of Inhalers in the Asthma and COPD Market
11.4.6 Research Emphasis on COPD?
11.4.7 Combinations for COPD
11.4.8 Views on Telehealth
11.4.9 Views on Personalised Medicine
11.4.10 On Novel Targets
11.4.11 The Ten-Year Outlook for the Asthma and COPD Market
11.5 Interview with Barbara Yawn, Director of Research at Olmsted Medical Center and Adjunct
Professor, Department of Family and Community Health, University of Minnesota, USA
11.5.1 Unmet Needs in Asthma
11.5.2 The Impact of Inhalers in Asthma and COPD
11.5.3 The Impact of New Drug Classes for COPD
11.5.4 Towards Personalised Medicine in Asthma and COPD
11.5.5 Views on Leukotriene Inhibitors
11.5.6 Anti-Inflammatory Drugs: More Research Required
www.visiongain.com
Contents
11.5.7 LABA Monotherapy Drugs: Fading Away?
11.5.8 LABA/LAMA Combination Drugs in COPD
11.5.9 Views On Telehealth
11.5.10 Under-Diagnosis in COPD
11.5.11 The Ten-Year Outlook for the Asthma and COPD Market
11.6 Interview with Ahmed Wagih, Product Manager, Respiratory Franchise (Seretide, Flixotide
and Ventolin) at GSK, UK
11.6.1 Rising Prevalence of COPD in the Middle East
11.6.2 Towards Personalised Medicine
11.6.3 Changes to Treatment Guidelines for Asthma and COPD
11.6.4 Key Areas of Focus in Asthma and COPD
11.6.5 Views on Generic Competition
11.6.6 Improving COPD Diagnostics
11.6.7 Views on LAMA/LABA Combinations
11.6.8 Views on Telehealth
12. Conclusions
12.1 Asthma and COPD Therapies: A Maturing Market
12.2 The World Asthma and COPD Therapies Market in 2013
12.2.1 Current Leading Asthma and COPD Therapies Segments
12.2.2 Leading Asthma and COPD Therapies
12.2.3 Leading Asthma and COPD Therapies Companies
12.2.4 Leading Regional and National Markets
12.3 World Asthma and COPD Therapies Market Forecast 2014-2024
12. Conclusions
www.visiongain.com
Contents
12.4 Asthma and COPD Therapies Late-Stage Pipeline
12.5 The Future of the Asthma and COPD Therapies Market?
12.5.1 Growth in Anti-Inflammatory and Combination Drugs
12.5.2 Towards Personalised Medicine
12.5.3 Unmet Needs in Asthma and COPD
12.5.4 Strategies for Growth in 2014-2024
www.visiongain.com Page 122
Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for Leading Companies
4.9 Mexican Asthma and COPD Therapies Market 2014-2024
Factors underlying the prevalence of asthma and COPD in Mexico include air pollution,
industrialisation and urbanisation, and a growing population. Air pollution is a widespread and
worsening problem in urban areas. The prevalence of asthma is higher in Mexico’s coastal states,
which may be due to the higher humidity causing dust to be suspended in the air and enter the
lungs more easily, or to the use of air conditioning systems that trap dust and moulds. There is also
a high rate of smoking, particularly in young people.
4.9.1 Mexican Asthma and COPD Therapies Market Forecast 2014-2024
Visiongain estimates that in 2013, the Mexican asthma and COPD therapies market reached
$309m, representing 0.9% of the world market. In 2014 the Mexican market will increase to
$320m, up 3.5% on 2013. Like Brazil, the Mexican market is characterised by improving healthcare
provision and higher cost-sensitivity. Generic drugs for asthma and COPD are expected to gain
market share in the Mexican market. In August 2014 Mexico was the first Latin American market to
approve Novartis/Vectura’s generic version of Advair. The drug will be marketed as IrFlosol
ForSpiro in Mexico. Improvements to the Mexican drug approval process will also drive the market,
visiongain believes. Visiongain predicts that the Mexican market will grow with a CAGR of 4.5%
over 2013-2018 to reach $385m in 2018. The Mexican market will grow at a CAGR of 5.3% over
2018-2024 to reach $525m in 2024, representing an overall CAGR of 4.9% over 2013-2024.
Table 4.20 and Figure 4.23 show visiongain’s forecast for the Mexican asthma and COPD
therapies market from 2013 to 2024.
Table 4.20 Mexican Asthma and COPD Therapies Market Forecast: Revenues ($m), AGR (%), CAGR (%), 2013-2024
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Mexico ($m) 309 320 333 347 363 385 402 423 454 486 507 525Annual Growth Rate (%) 3.5 4.0 4.3 4.4 6.2 4.5 5.0 7.5 7.0 4.2 3.6CAGR (%, 2013-2018 and 2018-2024)
4.5 5.3
CAGR (%, 2013-2024) 4.9 Source: visiongain 2014
www.visiongain.com Page 181
Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for Leading Companies
As discussed in Chapter 8, GSK is developing fluticasone furoate as a phase 3 pipeline compound
for asthma.
6.5.4.1 Flixotide/Flovent: Sales Forecast 2014-2024
Table 6.8 and Figure 6.12 show visiongain’s estimates of Flixotide/Flovent revenues over 2013-
2024.
Table 6.8 GSK: Flixotide/Flovent Revenue ($m), AGR (%), CAGR (%), 2013-2024
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024Flixotide/Flovent ($m) 1,245 1,283 1,321 1,349 1,376 1,307 1,242 1,192 1,144 1,110 1,088 1,077 Annual Growth Rate (%) 3.0 3.0 2.1 2.0 -5.0 -5.0 -4.0 -4.0 -3.0 -2.0 -1.0CAGR (%, 2013-2018 and 2018-2024)
1.0 -3.2
CAGR (%, 2013-2024) -1.3
Figure 6.12 GSK: Flixotide/Flovent Revenue ($m), AGR (%), 2013-2024
Flixotide/Flovent has been maintaining revenues at around $1,250m in USD terms in recent years,
and has had little direct mention in GSK’s financial reports. GSK reported Flixotide/Flovent
revenues of $1,245m in 2013. Visiongain estimates that sales for 2014 will reach $1,283m, up
3.0% on 2013. We predict that Flixotide/Flovent revenues will grow with a CAGR of 1.0% over
2013-2018 to reach $1,307m in 2018. The wide-ranging use of this drug across disease severity,
-6.0-5.0-4.0-3.0-2.0-1.00.01.02.03.04.0
0
200
400
600
800
1,000
1,200
1,400
1,600
2013 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
AGR
(%)
Sale
s ($
m)
Year Sales ($m) AGR (%)
Source: visiongain 2014
Source: visiongain 2014
www.visiongain.com Page 247
Asthma and COPD Therapies Market Forecast 2014-2024: Opportunities for Leading Companies
8.5 Merck & Co. (Merck)
Merck & Co., Inc. (Merck) is a leading US pharmaceutical and healthcare company. Its business
activities are organised by product segment into Pharmaceuticals, Animal Health, Consumer Care
and Alliances. Its position in the asthma and COPD market has declined significantly in 2014 due
to patent expiry of Singulair. Table 8.15 provides an overview of Merck.
Table 8.15 Merck: Overview, 2014
Ranking in 2013 4Company Merck & Co., Inc. (Merck)
Notable Subsidiaries Schering-Plough (2009), Inspire Pharmaceuticals (2011)
Business Areas Pharmaceuticals, consumer health, vaccines, animal health
Established 1917 (initially in 1891, the US subsidiary of Merck KGaA)
Headquarters Whitehouse Station, New Jersey, US
Leading Drugs Singulair, Proventil, Asmanex, Dulera, Foradil
FY 2013 Revenue ($m) 44,033
FY 2013 Asthma & COPD Drugs Revenue ($m) 1,976
8.5.1 Merck: Asthma and COPD Therapies
The revenues and revenue shares of Merck’s leading drugs in 2013 are shown in Table 8.16 and
Figures 8.16 and 8.17.
Table 8.16 Merck: Asthma and COPD Therapies Revenue ($m), Revenue Share (%) by Drug, 2013
Drug Revenue ($m) 2013 Revenue Share (%) 2013Singulair 1,196 60.5Dulera 324 16.4Asmanex 184 9.3Proventil 174 8.8Foradil (Merck) 98 5.0Total 1,976 100.0
Source: Merck & Co. 2014; visiongain 2014
Source: Merck 2014; visiongain 2014
Recommended